HWAIL PHARM (061250) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, HWAIL PHARM (061250) reported revenue of 100.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025100.8 billion KRW-2.3 billion KRW-233 million KRW[source]
2024119.8 billion KRW755 million KRW6.5 billion KRW[source]
2023122.5 billion KRW2.0 billion KRW3.9 billion KRW[source]
2022132.1 billion KRW4.8 billion KRW-6.3 billion KRW[source]
2021107.0 billion KRW4.3 billion KRW2.8 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025213.2 billion KRW6.3 billion KRW206.9 billion KRW[source]
2024215.6 billion KRW12.2 billion KRW203.4 billion KRW[source]
2023186.0 billion KRW11.5 billion KRW174.5 billion KRW[source]
2022185.6 billion KRW10.0 billion KRW175.6 billion KRW[source]
2021194.1 billion KRW12.5 billion KRW181.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice